Lexeo Therapeutics Common StockNASDAQ: LXEO

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

03 November 2023

Next earnings report:

11 March 2025

Last dividends:

N/A

Next dividends:

N/A
$219.89 M
-64%vs. 3y high
55%vs. sector
-vs. 3y high
-vs. sector
-62%vs. 3y high
52%vs. sector
-vs. 3y high
-vs. sector

Price

after hours | Fri, 15 Nov 2024 21:00:11 GMT
$6.65-$1.40(-17.39%)

Dividend

No data over the past 3 years

Analysts recommendations

Institutional Ownership

LXEO Latest News

Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results
globenewswire.com13 November 2024 Sentiment: POSITIVE

Reached alignment with FDA on key elements of registrational development plan for LX2006, including accelerated approval pathway with left-ventricular mass index (LVMI) and frataxin protein expression as co-primary registrational endpoints Received RMAT designation for LX2006 for the treatment of Friedreich ataxia (FA) cardiomyopathy, potentially enabling expedited development and increased interaction with the FDA Completed enrollment of LX2006 SUNRISE-FA Phase 1/2 trial, with four participants treated in cohort 3; total of 16 participants dosed with LX2006 to date across SUNRISE-FA and Weill Cornell trials Completed enrollment of cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial; initial clinical data including safety and biodistribution on track for late Q1 / early Q2 2025 Appointed Tolga Tanguler to Board of Directors, an accomplished biopharmaceutical executive with over 25 years of senior leadership experience Cash and cash equivalents of $157.0 million expected to provide operational runway into 2027 NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) --  Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today provided business updates across its portfolio of programs and reported third quarter 2024 financial results. “We have made significant progress over the last few months across all our clinical stage programs, including reaching alignment with the FDA on registrational endpoints to support an accelerated approval pathway for LX2006.

Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference
globenewswire.com22 October 2024 Sentiment: POSITIVE

NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that interim data from the ongoing Phase 1/2 trial (NCT03634007) of LX1001 have been selected as a late-breaking oral presentation at the Clinical Trials on Alzheimer's Disease (CTAD) conference taking place October 29 - November 1, 2024, in Madrid, Spain. The presentation will include new safety and biomarker data from four dose cohorts of LX1001, an AAVrh10-based gene therapy candidate designed to deliver the protective APOE2 gene into the central nervous systems of APOE4 homozygotes with Alzheimer's disease.

Lexeo Therapeutics to Participate in Upcoming Investor Conferences
globenewswire.com05 September 2024 Sentiment: POSITIVE

NEW YORK, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage genetic medicine company dedicated to pioneering treatments for genetically defined cardiovascular diseases and APOE4-associated Alzheimer's disease, today announced that Lexeo management will participate in corporate presentations and fireside chats at the following investor conferences:       H.C.

Lexeo (LXEO) Down Despite Upbeat Rare Disease Gene Therapy Data
zacks.com16 July 2024 Sentiment: POSITIVE

Interim data from an early-stage study shows that treatment with Lexeo's (LXEO) experimental gene therapy reduced signs of heart complications in patients with Friedreich's ataxia.

Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
globenewswire.com15 July 2024 Sentiment: POSITIVE

Achieved mean reduction in left ventricular mass index (LVMI) of 11.4% at 12 months and 18.3% at  18 months in participants with elevated LVMI at baseline

What Makes Lexeo Therapeutics, Inc. (LXEO) a New Buy Stock
Zacks Investment Research14 May 2024 Sentiment: POSITIVE

Lexeo Therapeutics, Inc. (LXEO) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

Wall Street Analysts Think Lexeo Therapeutics, Inc. (LXEO) Could Surge 57.82%: Read This Before Placing a Bet
Zacks Investment Research14 May 2024 Sentiment: POSITIVE

Analysts' price targets for Lexeo Therapeutics, Inc. (LXEO) suggest a potential 57.8% increase in the stock. Although this metric has not always been accurate, the consensus among analysts in raising earnings estimates does signal a positive outlook for the stock.

Lexeo: Targeted Alzheimer's Disease Treatment Approach Might Pay Off
Seeking Alpha09 April 2024 Sentiment: POSITIVE

Lexeo Therapeutics, Inc. anticipates releasing results from its SUNRISE-FA study using LX-2006 for FA cardiomyopathy patients in mid-2024. Results from all cohorts of the LEAD study using LX-1001 for homozygous APOE4 AD patients are expected in the second half of 2024. The global market for Alzheimer's Disease is projected to reach $9.73 billion by 2030, with an estimated 15% to 25% of AD patients carrying this allele.

LXEO Stock Earnings: Lexeo Therapeutics Reported Results for Q3 2023
InvestorPlace11 December 2023 Sentiment: NEGATIVE

Lexeo Therapeutics (NASDAQ: LXEO ) just reported results for the third quarter of 2023. Lexeo Therapeutics reported earnings per share of -$12.36.

Lexeo Therapeutics' stock falls 15% in trading debut after its IPO priced below range
Market Watch03 November 2023 Sentiment: NEGATIVE

Lexeo Therapeutics Inc.'s stock LXEO, -15.01% tumbled 15% in its trading debut on Friday, after the company's initial public offering priced below the proposed price range. The stock priced at $11, below a $13 to $15 range.

What type of business is Lexeo Therapeutics Common Stock?

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

What sector is Lexeo Therapeutics Common Stock in?

Lexeo Therapeutics Common Stock is in the Healthcare sector

What industry is Lexeo Therapeutics Common Stock in?

Lexeo Therapeutics Common Stock is in the Biotechnology industry

What country is Lexeo Therapeutics Common Stock from?

Lexeo Therapeutics Common Stock is headquartered in United States

When did Lexeo Therapeutics Common Stock go public?

Lexeo Therapeutics Common Stock initial public offering (IPO) was on 03 November 2023

What is Lexeo Therapeutics Common Stock website?

https://www.lexeotx.com

Is Lexeo Therapeutics Common Stock in the S&P 500?

No, Lexeo Therapeutics Common Stock is not included in the S&P 500 index

Is Lexeo Therapeutics Common Stock in the NASDAQ 100?

No, Lexeo Therapeutics Common Stock is not included in the NASDAQ 100 index

Is Lexeo Therapeutics Common Stock in the Dow Jones?

No, Lexeo Therapeutics Common Stock is not included in the Dow Jones index

When was Lexeo Therapeutics Common Stock the previous earnings report?

No data

When does Lexeo Therapeutics Common Stock earnings report?

The next expected earnings date for Lexeo Therapeutics Common Stock is 11 March 2025